TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00113633

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Subjects
Description: The subject's family will view a brief educational video about asthma control and therapy developed using provider and patient focus groups; a mailed reminder will be sent to the family to schedule a follow-up appointment.
Study: NCT02110355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 232
Description: Given as an oral tablet in escalating doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 232
Description: Given as an oral tablet in escalating doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib is an anti-cancer agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib is an anti-cancer agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trametinib
Description: Trametinib is an anti-cancer agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib is an anti-cancer agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabrafenib
Description: Dabrafenib is an anti-cancer agent
Study: NCT01116466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiGait
Description: ActiGait - implantable drop foot stimulator
Study: NCT01964495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Discontinuation of treatment according to CRP levels
Description: The cutoff point is a CRP below 100 mg/L and a reduction to 50% of the initial value.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Discontinuation of treatment according to PCT levels
Description: The cutoff point is a PCT below 0.25 mcg/L or a reduction to 10% of the initial value.
Study: NCT00026195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study: NCT01786499

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Relaxation Response Training
Study: NCT01964495

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment according to current guidelines
Description: Often a 7 days course of antibiotics, treatment may be extended if the attending physician deems it necessary.
Study: NCT04657705

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High power ablation
Description: High power ablation parameters (50-55 W)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard ablation power
Description: Standard ablation power parameters (40-45 W)
Study: NCT03730233

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hiatal hernia repair by tension-free mesh closure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hiatal hernia repair by simple suturing
Study: NCT02498054

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education with new meter feature.
Description: The blood glucose meter has default settings for the colour range indicator which can be customized by the subjects and/or their healthcare professional. This colour range indicator will be presented to the subjects as a computer simulation to show subjects a range of typical blood glucose values and how this new feature would classify these results as being low (blue), in-range (green) or high (red).
Study: NCT01634880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Postoperative Radiotherapy and Panitumumab
Description: The starting panitumumab dose is 2.5 mglkg given once a week. The total dose may be rounded up or down by no greater than 10 mg. The panitumumab dose will be calculated based on the subject's actual weekly body weight.~Standard radiation 64-70Gy with 2.0 Gy daily fractions in 6-7 weeks. Panitumumab 2.5 mg/Kg IV, weekly during radiation (total of 6-7 doses).
Study: NCT02286804

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultherapy
Description: Micro-focused ultrasound energy delivered below the surface of the skin
Study: NCT01268592

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: oocyte vitrification
Description: freezing of the patient's retrieved oocytes via vitrification (rapid freezing)
Study: NCT02495805

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous proximal adductor canal block
Description: Subjects will be randomized into 2 groups: those who will receive a continuous proximal adductor canal block (ACB) and those who will receive a continuous femoral nerve block (FNB).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous femoral nerve block
Description: Subjects will be randomized into 2 groups: those who will receive a continuous proximal adductor canal block (ACB) and those who will receive a continuous femoral nerve block (FNB).
Study: NCT04383405

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic Training
Description: Aquatic Training training consists of a sequential and a preparatory approach aimed at enhancing dynamic postural stability. The exercises follow a specific sequence starting from a kneeling position, proceeding to a sitting position and ending with a supine position. Step exercises preparatory for gait were performed using a step and two floating aids. Gait exercises were performed first with the upper limbs placed on two floating aids and then during a dual motor task (i.e. catching a ball thrown by the therapist). Subjects performed three sessions a week for four weeks and each session lasting 45 minutes. The training was carried out by a physiotherapist who had at least 5 years of experience in aquatic neurorehabilitation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Training
Description: Conventional land-based therapy consists of customized exercises focused on static and dynamic postural stability improvement. The exercises included the active-assisted mobilization, the muscle stretching the postural transition, the balance and the gait training. The control approach was carried out three times a week for four weeks and each session lasted 45 minutes.
Study: NCT02523170

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AQ-Flex 19 probe (Mauna Kea Technologies, Paris)
Description: Needle-based Confocal Laser Endomicroscopy (nCLE)
Study: NCT01780649

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IMSI
Description: Intracytoplasmic Morphologically Selected Sperm Injection (IMSI) is a modification of IntraCytoplasmic Sperm Injection (ICSI) with a choice of the spermatozoon to be injected done at a 6000x magnification instead of 400x commonly used in ICSI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ICSI
Description: ICSI is largely choice of the spermatozoon to be injected done at a 400x magnification
Study: NCT04098575

Intervention type: DRUG
Intervention: Empagliflozin
Description: drug
Study: NCT02810860

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic cholecystectomy
Description: Administration of a disease-specific and generic PROMs survey to patients undergoing Laparoscopic Cholecystectomy
Study: NCT04098575

Intervention type: DRUG
Intervention: Empagliflozin
Description: drug

Intervention type: DRUG
Intervention: Empagliflozin
Description: drug
Study: NCT02988193

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: optima4BP Medication Management
Description: A clinical reasoning expert system is used to determine the need for a medication treatment optimization. If a treatment optimization is needed, the expert system generates a recommendation that is sent to the treating physician.
Study: NCT00031720

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy protein
Description: Given orally
Study: NCT02998931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamin
Description: Enteral Glutamine 0.3g/kg/day powdered glutamine to be mixed in with water and given via nasogastric tube q4 hrs
Study: NCT00031720

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: isoflavones
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tamoxifen

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT00372775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 37.5 mg daily by oral capsule in a continuous regimen until progression or unacceptable toxicity
Study: NCT03875313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-839
Description: CB-839 oral tablets administered twice daily with food at the assigned dose level on 28 day cycles with talazoparib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-839
Description: CB-839 oral tablets administered twice daily with food at the assigned dose level on 28 day cycles with talazoparib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-839
Description: CB-839 oral tablets administered twice daily with food at the assigned dose level on 28 day cycles with talazoparib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-839
Description: CB-839 oral tablets administered twice daily with food at the assigned dose level on 28 day cycles with talazoparib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-839
Description: CB-839 oral tablets administered twice daily with food at the assigned dose level on 28 day cycles with talazoparib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib oral tablets administered at the standard dose once daily with or without food on 28 day cycles with CB-839.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib oral tablets administered at the standard dose once daily with or without food on 28 day cycles with CB-839.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib oral tablets administered at the standard dose once daily with or without food on 28 day cycles with CB-839.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib oral tablets administered at the standard dose once daily with or without food on 28 day cycles with CB-839.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib oral tablets administered at the standard dose once daily with or without food on 28 day cycles with CB-839.
Study: NCT00047125

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study: NCT02998931

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin mixed with water given via NG tube Q 4 hours
Study: NCT00692159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC102 + pemetrexed
Description: Oral TRC102 solution + IV pemetrexed
Study: NCT00047125

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT02890524

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: night guard
Description: 60 days before and after intervention with the night guard

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo night guard
Description: 60 days before and after intervention with the placebo night guard
Study: NCT03443700

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EKSO-GT
Description: Each rehabilitation session with EKSO-GT will last (operating time) 30-40 minutes. Such training will be carried out for 3 sessions per week, during the first 4 consecutive weeks of the study period (i.e. 12 total sessions per patient).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard neurorehabilitation locomotor training
Description: Neurorehabilitation locomotor training will be performed according to standardized protocols shared within the scientific community, during the whole 8-week study period, 5 times per week, twice a day, for a total of about 2,5 hours per day.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard neurorehabilitation locomotor training
Description: Neurorehabilitation locomotor training will be performed according to standardized protocols shared within the scientific community, during the whole 8-week study period, 5 times per week, twice a day, for a total of about 2,5 hours per day.
Study: NCT04407884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soovu Labs Inc. Pain Relief System
Description: Longnitual follow-up
Study: NCT03416036

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TetraVax-DV-TV003 (TV003)
Description: TV003 contains 10\^3.3 plaque-forming units (PFU)/mL of rDEN1Δ30, 10\^3.3 PFU/mL of rDEN2/4Δ30(ME), 10\^3.3 PFU/mL of rDEN3Δ30/31-7164, and 10\^3.3 PFU/mL of rDEN4Δ30. Administered by subcutaneous injection in the deltoid region of the upper arm
Study: NCT00428805

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: classroom curriculum
Description: classroom curriculum for 3 \& 4 year old children includes activities to increase intake of fruits, vegetables, \& whole grains; increase physical activity; decrease intake of fats and sugared drinks; and decrease screen time following monthly learning modules.~Teachers are trained to carry out the classroom curriculum.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-service training for Head Start teachers/aides
Description: Teachers and teacher aides are trained quarterly by certified trainers and receive a certificate for participating in the training. Topics include the content as well as developmental concepts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training for Head Start food service
Description: Food service workers are trained (quarterly) to modify food ordering, food preparation, and food serving to match the aims of the study

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family intervention component
Description: Families receive the CHILE intervention quarterly at Family Events. These include family activities to increase intake of fruits, vegetables, whole grains, decrease intake of fats and sugared drinks, increase of physical activity and decrease screen time. Parenting skills are also included.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food source
Description: The grocery store component includes field trips, self labeling, and taste testing of promoted foods.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health care providers
Description: The health care provider component includes the health care providers presenting at the Family Events and reinforcing the CHILE intervention message in the practice setting when talking with families of head start children.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHILE Head Start Intervention
Description: There are six components of this transcommunity social-ecological intervention including a classroom curriculum, health care provider component, family component, training of Head Start teachers/aides, training of food service staff and grocery store component.
Study: NCT03416036

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TetraVax-DV-TV003 (TV003)
Description: TV003 contains 10\^3.3 plaque-forming units (PFU)/mL of rDEN1Δ30, 10\^3.3 PFU/mL of rDEN2/4Δ30(ME), 10\^3.3 PFU/mL of rDEN3Δ30/31-7164, and 10\^3.3 PFU/mL of rDEN4Δ30. Administered by subcutaneous injection in the deltoid region of the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN2Δ30-7169 (DENV-2)
Description: Administered at a dose of 10\^3 PFU by subcutaneous injection in the deltoid region of the upper arm

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: rDEN2Δ30-7169 (DENV-2)
Description: Administered at a dose of 10\^3 PFU by subcutaneous injection in the deltoid region of the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN3Δ30 (DENV-3)
Description: Administered at a dose of 10\^3 PFU by subcutaneous injection in the deltoid region of the upper arm

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: rDEN3Δ30 (DENV-3)
Description: Administered at a dose of 10\^3 PFU by subcutaneous injection in the deltoid region of the upper arm

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection in the deltoid region of the upper arm

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection in the deltoid region of the upper arm
Study: NCT02292888

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive Leg Raising (PLR) test
Description: Passive Leg Raising (PLR) test

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive Leg Raising (PLR) test
Description: Passive Leg Raising (PLR) test
Study: NCT02892734

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00171730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Study: NCT01985867

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei rhamnosus Lcr35
Description: Eligible children will receive Lactobacillus casei rhamnosus Lcr35 (8×10\^8 CFU, twice daily, orally for 4 weeks)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible children will receive placebo (maltodextrin), twice daily, orally for 4 weeks
Study: NCT00808977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dersalazine sodium
Description: Dersalazine sodium 2400 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine
Description: Mesalazine 2400 mg daily
Study: NCT01616342

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal cord stimulator
Description: Precise (TM) spinal cord stimulator from boston scientific, and comprehensive mdedical management.
Study: NCT00808977

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching active and experimental treatments
Study: NCT00869453

Intervention type: OTHER
Intervention: test meal
Description: Mixed meal containing bread, butter, beef
Study: NCT03994783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 2 intravenous infusions of rituximab or approved biosimilar given 14 days +/- 2 days apart.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Intravenous infusion of methylprednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Intravenous infusion of methylprednisolone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Immunoglobulin
Description: High dose (2 g/kg total) or Low dose (100 mg/kg, n=7)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Immunoglobulin
Description: High dose (2 g/kg total) or Low dose (100 mg/kg, n=7)
Study: NCT02892734

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT02728310

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: An infusion rate of 10 ml/h of 1500 mg of 0.5 % of levobupivacaine for the first 30 h and 5 ml/h for the second 30 h (LCWI) were injected into the surgical wound.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: An infusion rate of 10 ml/h of 300 ml of saline solution for the first 30 h and 5 ml/h for the second 30 h (LCWI) were injected into the surgical wound.
Study: NCT03994783

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plasma Exchange
Description: Blood is removed from the patient and filtered to remove the plasma. Red and white blood cells and platelets are returned to the patient with replacement fluid.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasma Exchange
Description: Blood is removed from the patient and filtered to remove the plasma. Red and white blood cells and platelets are returned to the patient with replacement fluid.
Study: NCT03303196

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bihormonal Bionic Pancreas
Description: A 4-day inpatient admission in which subjects will wear the bihormonal pancreas. The bihormonal pancreas will be placed upon admission and there will be 1 day of run-in. This will be followed by 3 days of data collection for comparison with the data obtained from the standard of care during the control admission.
Study: NCT03253055

Intervention type: RADIATION
Intervention: DEXA
Description: Dual energy X-ray absorptiometry (DEXA): a total of two scans will be performed, one for the assessment of whole body bone mineral density and body composition, and the other scan is performed to specifically assess fracture risk by scanning the hip and femoral head. Effective exposure doses for these scans are \~8uSv and \~4uSv respectively.

Intervention type: RADIATION
Intervention: DEXA
Description: Dual energy X-ray absorptiometry (DEXA): a total of two scans will be performed, one for the assessment of whole body bone mineral density and body composition, and the other scan is performed to specifically assess fracture risk by scanning the hip and femoral head. Effective exposure doses for these scans are \~8uSv and \~4uSv respectively.

Intervention type: RADIATION
Intervention: DEXA
Description: Dual energy X-ray absorptiometry (DEXA): a total of two scans will be performed, one for the assessment of whole body bone mineral density and body composition, and the other scan is performed to specifically assess fracture risk by scanning the hip and femoral head. Effective exposure doses for these scans are \~8uSv and \~4uSv respectively.

Intervention type: RADIATION
Intervention: pQCT
Description: A total of one scan will be performed on the non-dominant Tibia, the effective exposure dose will be between 1.5-1.8uSV.

Intervention type: RADIATION
Intervention: pQCT
Description: A total of one scan will be performed on the non-dominant Tibia, the effective exposure dose will be between 1.5-1.8uSV.
Study: NCT03855787

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ureteroscopy
Description: Ureteroscopy for 1.5cm or less renal stones.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ureteroscopy
Description: Ureteroscopy for 1.5cm or less renal stones.
Study: NCT02591537

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OxyGenesys Dissolved Oxygen Dressing
Description: 1/2 of the abdominal wounds will be covered with Oxygenesys Dissolved Dressing.
Study: NCT03222362

Intervention type: OTHER
Intervention: Surgery
Study: NCT05407649

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy Combined with GM-CSF
Description: Patients with stable or progressing metastatic thymic epithelial tumours, with at least two distinct measurable sites of disease, were treated with concurrent radiotherapy (35 Gy in ten fractions or 60Gy in 30 fractions) to one metastatic site and granulocyte-macrophage colony-stimulating factor (125 μg/m(2) subcutaneously injected daily for 2 weeks, starting during the second week of radiotherapy).